Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer
Phase 3
Completed
- Conditions
- Lung CancerLymph Node Metastasis
- Interventions
- Drug: 99mTc-3PRGD2 injection
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- RDO Pharm.
- Target Recruit Count
- 409
- Registration Number
- NCT04233476
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: 99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- RDO Pharm.
- Target Recruit Count
- 10
- Registration Number
- NCT03974685
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
News
No news found